PDCD1 and cancer: Chen et al. (2021[15]) conducted a meta-analysis of 91 clinical trials to assess the effectiveness of PD-1/PD-L1 inhibitors in various clinical scenarios, quantifying overall response rate, time to response, and duration of response across different cancers, treatment lines, drug combinations, and regimens.